| Literature DB >> 29915213 |
Xiaomeng Yin1, Beisha Tang1,2,3,4,5,6,7, Xiao Mao1, Jinxin Peng1, Sheng Zeng1, Yaqin Wang8, Hong Jiang1,2,3,4, Nan Li9,10.
Abstract
Mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are a family of enzymes that play critical roles in protein biosynthesis. Mutations in mt-aaRSs are associated with various diseases. As a member of the mt-aaRS family, PARS2 encoding prolyl-tRNA synthetase 2 was recently shown to be associated with Alpers syndrome and certain infantile-onset neurodegenerative disorders in four patients. Here, we present two patients in a pedigree with early developmental delay, epileptic spasms, delayed myelination combined with cerebellar white matter abnormalities, and progressive cortical atrophy. Whole-exome sequencing revealed pathogenic compound heterozygous variants [c.283 G > A (p.95 V > I)] and [c.604 G > C (p.202 R > G)] in PARS2. Nearly all patients had epileptic spasms with early response to treatment, early developmental delay and/or regression followed by generalized hypotonia, postnatal microcephaly, elevated lactate levels, and progressive cerebral atrophy. Our study provides further evidence for validating the role of PARS2 in the pathology of related infantile-onset encephalopathy, contributing to the phenotypic features of this condition, and providing clinical and molecular insight for the diagnosis of this disease entity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29915213 DOI: 10.1038/s10038-018-0478-z
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172